MDxHealth SA said it has received a notification from the Listing Qualifications Department of The Nasdaq Stock Market indicating the company is not in compliance with Nasdaq’s minimum bid price requirement. The update, dated June 30, 2026, comes after the company failed to maintain a minimum closing bid price of US$1.00 per share for the requisite period, pushing its shares lower—continuing a weak trading pattern for the urology-focused diagnostics firm.
MDxHealth shares closed Thursday at $0.48, down 6.02%, and fell further in after-hours trading, according to market data, declining to $0.45.
Key takeaways
- Price move: MDxHealth closed at $0.48 and dropped again after hours to $0.45.
- Catalyst: Nasdaq notified the company of a minimum bid price deficiency under Listing Rule 5550(a)(2).
- Deadline: The company has until December 28, 2026 to regain compliance.
- Path to compliance: The shares must trade with a closing bid of at least $1.00 for 10 consecutive business days.
- Implication: Failure to meet the threshold could lead to delisting or additional regulatory steps, depending on eligibility for further time.
Nasdaq flags minimum bid price deficiency
According to the company’s notification, MDxHealth was found in violation of Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of US$1.00 per share. Nasdaq typically issues such notices after a security fails to hold the minimum bid price for 30 consecutive trading days or more.
The company said the notification was received on June 30, 2026, and that it has been provided a compliance window of 180 calendar days from the notice period, extending the deadline to December 28, 2026.
What MDxHealth must do to regain compliance
MDxHealth outlined the specific criterion for returning to compliance: its ordinary shares must achieve a closing bid price of at least $1.00 for a minimum of 10 consecutive business days.
If the company does not regain compliance by the stated date, MDxHealth said it may be eligible for additional time to regain compliance. If not eligible or if requirements are not met, the company could face delisting.
Market reaction and investor implications
While the notification is a procedural listing compliance matter, the market typically treats bid-price issues as a near-to-medium-term risk because they can quickly turn into liquidity and execution concerns for shareholders—especially for small-cap and development-stage names. The stock’s selloff on the day of the update suggests investors are focused on the probability and timing of reaching the $1 threshold within the compliance window.
MDxHealth’s share price closed at $0.48, meaning the company is currently about halfway to the minimum $1.00 level required for compliance. With after-hours trading also moving lower to $0.45, the immediate reaction indicates traders are not assuming a near-term turnaround based on the news alone.
Investors may also be watching for financing activity, corporate actions, and broader sentiment toward small-cap healthcare and diagnostics companies, since those factors can influence trading levels and help determine whether the stock can post the required series of $1+ closing bids.
Bigger picture: compliance risk remains in focus
Nasdaq’s minimum bid price rule is one of several mechanisms designed to maintain liquidity and orderly trading on the exchange. For companies facing a deficiency, the compliance timeline creates an event window where trading performance can become more sensitive to headlines and near-term catalysts—such as operational updates, clinical milestones, or fundraising—depending on the company’s business model.
For MDxHealth, the key variable is whether the stock can sustain a $1.00 closing bid for 10 consecutive business days before the December 28, 2026 deadline.
What to watch next: Investors will likely focus on whether MDxHealth can attract buying support sufficient to lift and maintain its closing bid price above $1.00 for the required stretch. With the Nasdaq compliance deadline set for December 28, 2026, the next meaningful signals may come from company updates, potential capital-raising actions, and any market developments that could affect trading liquidity.
